A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease
Blood · 2025
DOI: 10.1182/blood.2024028166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2025. Verfasst von Anne Chalumeau und 13 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Imagine Institute, Laboratory of Chromatin and Gene Regulation during Development, INSERM Unité Mixte de Recherche 1163, Paris…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Fetal Hemoglobin, gamma-Globins, Gene Editing. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Fetal hemoglobin reactivation is a promising therapy for β-hemoglobinopathies. We developed a prime editing strategy that introduces multiple mutations in the fetal γ-globin promoters that are expected to increase their activity. We tested multiple targets and optimized a variety of parameters to achieve ∼50% of precise edits in a hematopoietic cell line, with minimal off-target effects. This work improved our understanding of the complex DNA repair mechanisms involved in prime editing. We tested this strategy in patients’ hematopoietic stem/progenitor cells. Although editing efficiency was variable among donors, erythroid clones carrying multiple mutations expressed a significantly higher γ-globin level than cells carrying individual mutations, confirming the potential therapeutic benefit of our combined strategy for patients with β-hemoglobinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, Imagine Institute, Laboratory of Chromatin and Gene Regulation during Development, INSERM Unité Mixte de Recherche 1163, Paris, France.
- Genome Engineering, Discovery Sciences, Research and Development, AstraZeneca, Gothenburg, Sweden.
- Genethon, INSERM Unité Mixte de Recherche S951, Evry, France.
- Université Paris-Saclay, University of Évry Val d'Essonne, INSERM, Genethon, Integrare Research Unit Unité Mixte de Recherche S951, Evry, France.
- Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
- Département Adaptation du Vivant, Museum National d'Histoire Naturelle, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7196, INSERM Unité Mixte de Recherche 1154, Paris, France.
ORCID-Profile: Maria Bou Dames, Letizia Fontana, Simone Amistadi, Guillaume Corre, Martin Peterka, Mario Amendola, Annarita Miccio, Mégane Brusson
Zitieren
APA
Chalumeau, A., Bou Dames, M., Fontana, L., Amistadi, S., Antoniou, P., Loganathan, P., Mombled, M., Corre, G., Peterka, M., Amendola, M., Giovannangeli, C., Maresca, M., Miccio, A., & Brusson, M. (2025). A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease. Blood. https://doi.org/10.1182/blood.2024028166
Vancouver
Chalumeau A, Bou Dames M, Fontana L, Amistadi S, Antoniou P, Loganathan P, et al. A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease. Blood. 2025. doi:10.1182/blood.2024028166
BibTeX
@article{Chalumeau2025,
author = {Chalumeau, Anne and Bou Dames, Maria and Fontana, Letizia and Amistadi, Simone and Antoniou, Panagiotis and Loganathan, Priyanka and Mombled, Margaux and Corre, Guillaume and Peterka, Martin and Amendola, Mario and Giovannangeli, Carine and Maresca, Marcello and Miccio, Annarita and Brusson, Mégane},
title = {A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease},
journal = {Blood},
year = {2025},
doi = {10.1182/blood.2024028166}
}
EUVIMED